Journal article · 2024 · Open access

Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains

Malin Johannesson, Linda Söderberg, Olof Zachrisson, Nicolas Fritz, Helen Kylefjord, Eleni Gkanatsiou, Emily B. Button, Anne-Sophie Svensson, Adeline Rachalski, Patrik Nygren, Gunilla Osswald, Lars Lannfelt and 1 more

Molecular and Cellular Neuroscience, 130, 103949 · Published 20 June 2024 · DOI 10.1016/j.mcn.2024.103949

Open full textCite this paper

In brief

“Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains” is a 2024 journal article by Malin Johannesson and 12 co-authors, published in Molecular and Cellular Neuroscience. OpenAlex counts 75 citations as of 20 November 2026, which puts it in the top 2% of works published in 2024 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Molecular and Cellular Neuroscience.

Citations
75
Most cited in
2026 (41)
Field-weighted impact
8.94
References
35
Authors
13

Abstract

Recent advances in immunotherapeutic approaches to the treatment of Alzheimer's disease (AD) have increased the importance of understanding the exact binding preference of each amyloid-beta (Aβ) antibody employed, since this determines both efficacy and risk for potentially serious adverse events known as amyloid-related imaging abnormalities. Lecanemab is a humanized IgG1 antibody that was developed to target the soluble Aβ protofibril conformation. The present study prepared extracts of post mortem brain samples from AD patients and non-demented elderly controls, characterized the forms of Aβ present, and investigated their interactions with lecanemab. Brain tissue samples were homogenized and extracted using tris-buffered saline. Aβ levels and aggregation states in soluble and insoluble extracts, and in fractions prepared using size-exclusion chromatography or density gradient ultracentrifugation, were analyzed using combinations of immunoassay, immunoprecipitation (IP), and mass spectrometry. Lecanemab immunohistochemistry was also conducted in temporal cortex. The majority of temporal cortex Aβ (98 %) was in the insoluble extract. Aβ42 was the most abundant form present, particularly in AD subjects, and most soluble Aβ42 was in soluble aggregated protofibrillar structures. Aβ protofibril levels were much higher in AD subjects than in controls. Protofibrils captured by lecanemab-IP contained high levels of Aβ42 and lecanemab bound to large, medium, and small Aβ42 protofibrils in a concentration-dependent manner. Competitive IP showed that neither Aβ40 monomers nor Aβ40-enriched fibrils isolated from cerebral amyloid angiopathy reduced lecanemab's binding to Aβ42 protofibrils. Immunohistochemistry showed that lecanemab bound readily to Aβ plaques (diffuse and compact) and to intraneuronal Aβ in AD temporal cortex. Taken together, these findings indicate that while lecanemab binds to Aβ plaques, it preferentially targets soluble aggregated Aβ protofibrils. These are largely composed of Aβ42, and lecanemab binds less readily to the Aβ40-enriched fibrils found in the cerebral vasculature. This is a promising binding profile because Aβ42 protofibrils represent a key therapeutic target in AD, while a lack of binding to monomeric Aβ and cerebral amyloid deposits should reduce peripheral antibody sequestration and minimize risk for adverse events.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Johannesson, M., Söderberg, L., Zachrisson, O., Fritz, N., Kylefjord, H., Gkanatsiou, E., Button, E. B., Svensson, A.-S., Rachalski, A., Nygren, P., Osswald, G., Lannfelt, L., & Möller, C. (2024). Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Molecular and Cellular Neuroscience, 130, 103949. https://doi.org/10.1016/j.mcn.2024.103949

MLA 9

Johannesson, Malin, et al. “Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.” Molecular and Cellular Neuroscience, vol. 130, 2024, p. 103949. https://doi.org/10.1016/j.mcn.2024.103949.

Chicago

Johannesson, Malin, Linda Söderberg, Olof Zachrisson, Nicolas Fritz, Helen Kylefjord, Eleni Gkanatsiou, Emily B. Button, et al. 2024. “Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.” Molecular and Cellular Neuroscience 130: 103949. https://doi.org/10.1016/j.mcn.2024.103949.

Harvard

Johannesson, M. et al. (2024) ‘Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains’, Molecular and Cellular Neuroscience, 130, p. 103949. doi:10.1016/j.mcn.2024.103949.

IEEE

M. Johannesson et al., “Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains,” Molecular and Cellular Neuroscience, vol. 130, p. 103949, 2024, doi: 10.1016/j.mcn.2024.103949.

BibTeX

@article{johannesson2024lecanemab,
  title     = {{Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains}},
  author    = {Johannesson, Malin and Söderberg, Linda and Zachrisson, Olof and Fritz, Nicolas and Kylefjord, Helen and Gkanatsiou, Eleni and Button, Emily B. and Svensson, Anne-Sophie and Rachalski, Adeline and Nygren, Patrik and Osswald, Gunilla and Lannfelt, Lars and Möller, Christer},
  journal   = {Molecular and Cellular Neuroscience},
  year      = {2024},
  volume    = {130},
  pages     = {103949},
  doi       = {10.1016/j.mcn.2024.103949},
  url       = {https://doi.org/10.1016/j.mcn.2024.103949}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202499
20252525
20264141

Its field-weighted citation impact is 8.94: it has been cited 8.94 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • lecanemab
  • Alzheimer's disease
  • amyloid-beta protofibrils
  • amyloid-beta 42
  • Aβ40
  • antibody specificity
  • amyloid plaques
  • cerebral amyloid angiopathy

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Johannesson, M., Söderberg, L., Zachrisson, O., Fritz, N., Kylefjord, H., Gkanatsiou, E., Button, E. B., Svensson, A.-S., Rachalski, A., Nygren, P., Osswald, G., Lannfelt, L., & Möller, C. (2024). Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Molecular and Cellular Neuroscience, 130, 103949. https://doi.org/10.1016/j.mcn.2024.103949

How many times has this paper been cited?

75 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Molecular and Cellular Neuroscience: sign in and open the full text from this page.

Who wrote this paper?

Malin Johannesson, Linda Söderberg, Olof Zachrisson, Nicolas Fritz, Helen Kylefjord, Eleni Gkanatsiou, Emily B. Button, Anne-Sophie Svensson, Adeline Rachalski, Patrik Nygren, Gunilla Osswald, Lars Lannfelt and 1 more.

What is the DOI of this paper?

10.1016/j.mcn.2024.103949, permanently at https://doi.org/10.1016/j.mcn.2024.103949. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.